The suprachoroidal space: from potential space to a space with potential

Elad Moisseiev1–3
Anat Loewenstein2,3
Glenn Yiu1
1UC Davis Eye Center, University of California Davis, Sacramento, CA, USA; 2Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv; 3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract: Recent advances have made it possible to image the suprachoroidal space, and the understanding of its clinical applications is currently being greatly expanded. This opinion piece covers the advances in imaging techniques that enable the demonstration of the suprachoroidal space, and its implication in various retinal pathologies. It also reviews its potential uses as a route for drug delivery for the treatment of retinal diseases, and its use in innovative surgical techniques. Current research is leading the way for the suprachoroidal space to be an aspect of retinal disease diagnosis, monitoring, medical treatment, and surgical manipulation.

Keywords: suprachoroidal space, enhanced depth imaging, drug delivery, potential space

Introduction

The suprachoroidal space (SCS) has been long known as a potential space between the choroid and the sclera. While the inner border of the choroid, which is the Bruch’s membrane, is compact, the outer border is more a zone of transition, consisting of several fibrous lamellae with variable thickness.1 Until recently, the SCS could only be visualized on histology,2 and could only be demonstrated in vivo by ultrasonography in pathologic conditions such as idiopathic uveal effusion syndrome or posterior scleritis where excess fluid accumulation around the optic nerve results in a “T sign”.3 Optical coherence tomography (OCT) imaging has revolutionized the practice of ophthalmology in the past 2 decades, mostly for retinal conditions, and enabled detailed in vivo imaging of retinal structures with an axial resolution as high as 3 μm.4 Further advances in OCT technology have made it possible to clearly image not only the retina, but the layers underneath it. This is achieved by using enhanced depth imaging (EDI)-OCT, a technique that allows standard spectral-domain OCT instruments to visualize the choroid,5 or by swept-source OCT, which uses a longer wavelength that allows deeper penetration.6

These advanced imaging techniques have increased our understanding of retinal pathologies, demonstrating changes in choroidal thickness in a variety of conditions, such as central serous chorioretinopathy,7–11 polypoidal choroidal vasculopathy,12–14 myopic degeneration,15–16 and age-related macular degeneration (AMD).17–19 Choroidal imaging has also provided new insight on eyes with diabetic retinopathy, adult vitelliform pattern dystrophy, Stargardt’s disease, pseudophakic cystoid macular edema, and intraocular inflammation.20–24 They can be used to diagnose and monitor choroidal nevi and tumors, and even improve the detection of choroidal melanoma.25–29

Further advances have now made it possible to image the SCS in vivo (Figure 1) to reveal new insights into its role in healthy and pathologic eyes. The ability to accurately image the choroid has made it an integral component in the evaluation of retinal conditions, and we expect the same for the SCS. Importantly, the SCS may not only
be useful for diagnosis and monitoring but may also provide a new route for both medical and surgical treatments. The purpose of this opinion piece is to focus on the SCS and its evolving relevance to retinal specialists.

**Imaging the SCS**

The majority of studies on choroidal thickness have defined the inner border of the sclera as the outer boundary of the choroid. However, some researchers have noted a hyporeflective band between the outer border of the choroid and sclera, which may cause variability in choroidal thickness measurements. A recent study has identified this hyporeflective band to correspond to the SCS, and discussed the importance of its recognition to accurate measurement of choroidal thickness. The SCS can be demonstrated and accurately measured by both EDI-OCT and swept-source OCT, and has been shown to be present in approximately 50% of people above the age of 50 years. The presence of the SCS has been correlated to hyperopic refractive error, and is generally absent in the eyes of young, healthy persons. It has been theorized that in hyperopic eyes, there is increased hydrostatic pressure from compression of the vortex veins by the sclera, resulting in a subclinical suprachoroidal effusion that makes the small amount of fluid in the SCS visible on imaging. It has also been shown that with age there is an increase in leakage of proteins from choroidal vessels to the SCS, increasing its osmotic pressure as well, and results in the higher rates of its detection in older individuals.

The SCS has been reported to be demonstrated in 20%–50% of eyes with AMD. Except for the patients’ increased age, it has been suggested that choroidal thinning in AMD may increase the likelihood of SCS’s presence. Presence of SCS was also found in 50%–60% of patients with macular holes and epiretinal membranes, but this may be due to their age and not necessarily correlated to these conditions. It has also been shown that there is loculation of fluid in the outer choroid in approximately 65% of eyes with central serous chorioretinopathy. While the presence or thickness of the SCS in retinal diseases has not been fully elucidated, it may become another parameter that will be useful for their diagnosis and follow-up.

**The SCS as a route for drug delivery**

Intravitreal injections are currently the mainstay of treatment for a wide variety of retinal diseases, and constitute an effective method to achieve high intraocular levels of antibiotic, antiviral, antifungal, steroid, and anti-VEGF drugs. Intravitreal injections have a good safety profile, but it should be remembered that they can cause ocular complications, including cataract formation, glaucoma, choroidal hemorrhage, endophthalmitis, vitreous hemorrhage, and retinal detachment, and the injected drug can be absorbed and induce systemic adverse effects. Topical administration of drugs generally achieves low concentration in the vitreous, and is not commonly used for the treatment of retinal diseases. Systemic treatment is also limited, as the blood-retina-barrier limits the ability of the drugs to reach the eye, and high doses may cause systemic adverse effects. Periocular (subconjunctival, sub-Tenon, or retrobulbar) injections can bypass the blood-retina-barrier without intraocular penetration. However, the injected drug still has to traverse the sclera, which is less permeable to larger molecules, and may not achieve therapeutic drug levels at the level of the retina.

The SCS is an attractive route of drug delivery, which may enable bypassing the sclera without the risk of intraocular penetration. Animal studies have shown that the SCS can accommodate up to 1 mL of fluid, which rapidly diffused into the posterior segment. This volume is much larger than what is required for achieving therapeutic levels for clinically relevant drugs. Injections of 10–50 µL into the SCS have been demonstrated to be well tolerated with a low risk of ocular complications. OCT imaging of the SCS may also become a useful means of ensuring the injected drug was properly administered, as well as of following its pharmacokinetics. Suprachoroidal drug delivery to the vitreous has been shown to decline with an increase in drug lipophilicity and molecular weight. This evidence
makes the SCS an attractive route for drug delivery, as it may allow for larger volumes of drugs and longer duration of action to be achieved with a safer procedure. In addition, drug delivery through the SCS bypasses the internal limiting membrane barrier and outer blood-retina-barrier, and may be a preferred route for drug delivery targeting the retinal pigment epithelium.

Several techniques for injections into the SCS have been described. First, the injection can be done using standard small-gauge needles, but this is a delicate procedure and penetration into the choroid or the vitreous cavity is possible. Second, surgical cannulation has been shown to be effective and safe in achieving drug delivery to the posterior pole, but this is a complicated procedure that cannot be performed in-office. Finally, SCS drug delivery can be performed using microneedles—small-gauge needles (30–33 G) only 0.7–1.0 mm in length that are only long enough to penetrate the sclera and reach the SCS. These microneedles have been demonstrated to be safe and effective in several animal studies. Specifically, administration of corticosteroids via this route was shown to reduce intraocular inflammation, and anti-glaucoma agents were shown to reduce intraocular pressure. A microneedle for SCS injection in humans has been developed by Clearside Biomedical Inc. (Alpharetta, GA, USA), and a Phase 1/2 study evaluating the safety and tolerability of 4 mg/100 µL triamcinolone acetonide administered to the SCS in patients with noninfectious uveitis has been performed (clinicaltrials.gov NCT01789320; data not published yet). It is likely that in the near future, this will become a common route of drug delivery for the treatment of retinal diseases.

**Retinal surgery in the SCS**

Surgical utilization of the SCS has primarily been investigated for the treatment of glaucoma. This concept has been described over a century ago, when iatrogenic creation of a cyclodialysis cleft was performed to reduce intraocular pressure in patients with severe glaucoma, thus creating an alternate route of aqueous fluid passage into the SCS. Glaucoma surgery in the SCS has several important advantages over penetrating procedures. It can be entered by transscleral (external) or intracameral (internal) approaches, it does not disturb the conjunctiva or preclude subsequent surgeries, and has an increased safety profile. Several surgical techniques have been developed to use the SCS for glaucoma, such as a silicone drainage device that is implanted under a scleral flap and connects the anterior chamber and SCS, the Gold Micro Shunt which is implanted in the SCS, and several types of supraciliary microstents that are inserted through a clear corneal incision (often during cataract surgery) to create an internal connection from the anterior chamber to the SCS.

The SCS has not been the target of vitreoretinal surgeons, and was likely only accessed by them in complicated cases requiring surgical drainage of suprachoroidal hemorrhage. However, as technology and instrumentations continue to evolve, it may become useful and important in vitreoretinal surgery. For instance, it has been shown that injection of sodium hyaluronate into the SCS in patients with retinal detachment achieved choroidal detachment that lasted long enough to allow successful retinopexy. More recently, a technique of suprachoroidal buckling has been described, using an illuminated catheter inserted into the SCS and navigated to any desired location, where a long-lasting hyaluronic acid filler can be injected to create internal choroidal indentation. This technique can be performed without or in combination with vitrectomy, and has been successfully used for the treatment of patients with retinal detachment and myopic tractional maculopathies. Although pars plana vitrectomy and scleral buckles are effective surgical techniques, they may still cause complications such as pain, diplopia, refractive error shifts, cataract progression, glaucoma, vitreous hemorrhage, and endophthalmitis. Suprachoroidal buckling can be an elegant and relatively noninvasive technique that may become a useful adjunct to vitreoretinal surgery, although the technical difficulty may limit its widespread use for now.

Another aspect where the SCS may prove to be useful is retinal prostheses surgery. Retinal prostheses are electrical devices that can be implanted directly under or on top of the retina, and restore some vision in patients with severe visual loss. At present, several devices have been developed for this purpose, although only the Argus II system has been approved by the US Food and Drug Administration. Results from patients implanted with the Argus II demonstrated long-term efficacy and safety, and paved the way for further research into this field. Despite the encouraging results, it should be remembered that implantation of retina prostheses requires a complicated surgical procedure, that may be associated with significant complications. A retinal prosthesis that can be placed in the SCS would have the advantages of a simpler surgical procedure and increased safety profile. Recently, a prototype for a retinal prosthesis implanted in the SCS has been developed. The device consists of a conformable silicone substrate that holds 21 electrodes inserted into the SCS and placed under the macula. A wire exits through the sclera, and is passed...
through a tunnel dissected under the temporalis fascia to a percutaneous pedestal which is placed periauricularly.67 The device has been studied in cadaver and animal eyes,68 and recently reported to have resulted in some vision gain with a favorable safety profile in three human patients with end-stage retinitis pigmentosa.69 Further research into this type of retinal prosthesis is ongoing.

**Conclusion**

The SCS is receiving increasing attention, and its potential role in the diagnosis and treatment of various retinal conditions is being recognized. Technological advances have only recently made it possible for the SCS to be clearly imaged, and its variability in aging, health, and disease states is currently being understood. It is also emerging as a target for drug delivery and surgical procedures, spawning an array of novel devices for clinical use, from microneedles to retinal prostheses. It is likely that in the near future, the SCS will become a routine component in the diagnosis, monitoring, and treatment of retinal diseases, and it is likely that new discoveries regarding its potential uses will be made in the near future. In the meantime, we suggest clinicians try to identify and characterize the SCS in their patients’ OCT scans, as awareness of it holds the promise for interesting and clinically significant insights.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


34. Rahman W, Chen FK, Yeoh J, Patel P, Tufail A, Da Cruz L. Repeat


